{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:44:26Z","timestamp":1786995866174,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lentis Mental Health Care"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pnpbp.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T21:48:52Z","timestamp":1526593732000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Relation of inflammatory markers with symptoms of psychotic disorders: a large cohort study"],"prefix":"10.1016","volume":"86","author":[{"given":"E.J.","family":"Liemburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-828X","authenticated-orcid":false,"given":"H.C.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Knegtering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.006_bb0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.psychres.2008.06.010","article-title":"Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients","volume":"169","author":"Akanji","year":"2009","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.006_bb0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0706.2009.17726.x","article-title":"Comprehensive test of the \u2018limiting resources\u2019 framework applied to plant tolerance to apical meristem damage","volume":"119","author":"Banta","year":"2010","journal-title":"Oikos"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0015","series-title":"lme4: Linear Mixed-Effects Models Using Eigen and S4","volume":"2016","author":"Bates","year":"2014"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb9000","first-page":"320","article-title":"Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS)","author":"Bartels-Velthuis","year":"2018","journal-title":"Schizophr Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.006_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/2045125313511487","article-title":"Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study","volume":"4","author":"Chaudhry","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajp.2016.08.025","article-title":"Elevated copper, hs C-reactive protein and dyslipidemia in drug free schizophrenia: relation with psychopathology score","volume":"24","author":"Devanarayanan","year":"2016","journal-title":"Asian J. Psychiatr."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2010.06.002","article-title":"Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naive psychotic sample","volume":"121","author":"Diaz","year":"2010","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2007.03.022","article-title":"C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia","volume":"93","author":"Dickerson","year":"2007","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.006_bb0040","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2012.10.041","article-title":"C-reactive protein is elevated in schizophrenia","volume":"143","author":"Dickerson","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2012.06.040","article-title":"Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein","volume":"140","author":"Dieset","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.psychres.2006.07.011","article-title":"Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia","volume":"149","author":"Fan","year":"2007","journal-title":"Psychiatry Res."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2010.02.1028","article-title":"Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia","volume":"118","author":"Fan","year":"2010","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.006_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.psychres.2011.05.010","article-title":"C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia","volume":"190","author":"Fawzi","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0065","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/(SICI)1097-0258(19960830)15:16<1793::AID-SIM332>3.0.CO;2-2","article-title":"A comparison of statistical methods for clustered data analysis with Gaussian error","volume":"15","author":"Feng","year":"1996","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.04.006_bb0070","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/1617-9625-10-7","article-title":"Systemic inflammation in 222.841 healthy employed smokers and nonsmokers: white blood cell count and relationship to spirometry","volume":"10","author":"Fernandez","year":"2012","journal-title":"Tob. Induc. Dis."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.006_bb0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.psychres.2011.08.014","article-title":"Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features","volume":"198","author":"Garcia-Rizo","year":"2012","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.04.006_bb0085","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.006_bb0090","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.neubiorev.2009.09.004","article-title":"The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question","volume":"34","author":"Goghari","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"17","key":"10.1016\/j.pnpbp.2018.04.006_bb0095","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pnpbp.2018.04.006_bb0100","article-title":"Theories of schizophrenia: a genetic-inflammatory-vascular synthesis","volume":"6","author":"Hanson","year":"2005","journal-title":"BMC Med. Genet."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.006_bb0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/npp.2011.205","article-title":"Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior","volume":"37","author":"Haroon","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0110","series-title":"rms: Regression Modeling Strategies","volume":"2017","author":"Harrell","year":"2017"},{"issue":"12","key":"10.1016\/j.pnpbp.2018.04.006_bb0115","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/jamapsychiatry.2017.3191","article-title":"Inflammatory biomarkers and risk of schizophrenia: a 2-sample Mendelian randomization study","volume":"74","author":"Hartwig","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2018.04.006_bb0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.schres.2015.08.019","article-title":"Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups","volume":"168","author":"Joseph","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.pnpbp.2018.04.006_bb0130","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00213-015-3975-1","article-title":"Is there a role for immune-to-brain communication in schizophrenia?","volume":"233","author":"Khandaker","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0135","series-title":"lmerTest: Tests in Linear Mixed Effects Models","volume":"2017","author":"Kuznetsova","year":"2016"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.006_bb0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.npp.1300837","article-title":"Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia","volume":"31","author":"Lahti","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"9896","key":"10.1016\/j.pnpbp.2018.04.006_bb0145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2013.05.005","article-title":"Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment","volume":"45","author":"Lopresti","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2018.04.006_bb0155","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2018.04.006_bb0160","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.biopsych.2012.09.007","article-title":"Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects","volume":"73","author":"Miller","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbi.2012.08.016","article-title":"Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses","volume":"31","author":"Miller","year":"2013","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.04.006_bb0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-reactive protein levels in schizophrenia: a review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin. Schizophr. Relat. Psychoses."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.006_bb0175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pnpbp.2012.06.024","article-title":"Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia","volume":"39","author":"Na","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0180","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.schres.2016.08.024","article-title":"Low vitamin D is associated with negative and depressive symptoms in psychotic disorders","volume":"178","author":"Nerhus","year":"2016","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.04.006_bb0185","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.mp.4000889","article-title":"Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology","volume":"6","author":"Rothermundt","year":"2001","journal-title":"Mol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.04.006_bb0195","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1198\/108571102726","article-title":"Adequacy of approximations to distributions of test statistics in complex mixed linear models","volume":"7","author":"Schaalje","year":"2002","journal-title":"J. Agric. Biol. Environ. Stat."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.006_bb0200","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1503\/jpn.140126","article-title":"Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia\u2014significance for activation of the kynurenine pathway","volume":"40","author":"Schwieler","year":"2015","journal-title":"J. Psychiatry Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.006_bb0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eurpsy.2011.07.003","article-title":"C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice","volume":"28","author":"Sicras-Mainar","year":"2013","journal-title":"Eur. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.006_bb0210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.psychres.2014.02.004","article-title":"Role of C-reactive protein in schizophrenia: an overview","volume":"216","author":"Singh","year":"2014","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.006_bb0215","first-page":"6","article-title":"C-reactive protein (CRP) in patients with schizophrenia: are they related with symptomatology?","volume":"15","author":"Solanki","year":"2009","journal-title":"J. Ment. Health Hum. Behav."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.006_bb0220","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.psychres.2014.04.041","article-title":"A cross-national factor analytic comparison of three models of PANSS symptoms in schizophrenia","volume":"219","author":"Stefanovics","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.psyneuen.2013.12.005","article-title":"Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms","volume":"41","author":"Stojanovic","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1016\/j.pnpbp.2018.04.006_bb0230","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/oxfordjournals.aje.a008997","article-title":"Longitudinal relation between smoking and white blood cells","volume":"144","author":"Sunyer","year":"1996","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.006_bb0235","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.psychres.2011.07.006","article-title":"Inflammation in psychotic disorders: a population-based study","volume":"189","author":"Suvisaari","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0240","series-title":"A Package for Survival Analysis in S","volume":"2015","author":"Therneau","year":"2015"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0245","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.pnpbp.2018.04.006_bb0250","series-title":"Model Search and Inference by Bootstrap \u201cBumping\u201d","author":"Tibshirani","year":"1996"},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0255","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2014.08.021","article-title":"A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism","volume":"159","author":"Vincenzi","year":"2014","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.04.006_bb0260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/08039488.2012.745601","article-title":"Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia","volume":"67","author":"Vuksan-Cusa","year":"2013","journal-title":"Nord. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2018.04.006_bb0265","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000356536","article-title":"First-episode psychosis: an inflammatory state?","volume":"21","author":"Zajkowska","year":"2014","journal-title":"Neuroimmunomodulation"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618300551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618300551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:44:43Z","timestamp":1759520683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584618300551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":54,"alternative-id":["S0278584618300551"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.04.006","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation of inflammatory markers with symptoms of psychotic disorders: a large cohort study","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}